Press release
Merck KGaA: PharmaVitae Profile now available at ReportsandReports
Dallas, TX: ReportsandReports announce Merck KGaA: PharmaVitae Profile Market Research Report in its Store.Browse complete Report at: http://www.reportsandreports.com/reports/8512-merck-kgaa-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Merck KGaA's performance against key rivals in the prescription pharmaceutical sector
• Learn how the continued strong performance of Erbitux will drive the company's prescription pharma business in the period to 2015
• Evaluate the company's more focused business strategy and see how its extensive restructuring has affected its operating cost and profit margins
• CHAPTER 1 ABOUT THIS PROFILE 2
• Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
• CHAPTER 2 EXECUTIVE SUMMARY 4
• Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Merck KGaA: PharmaVitae forecasts at a glance 7
Strategic insight 8
Erbitux and Serono acquisition rejuvenate branded Rx pharma business 8
and diversify Merck KGaA's portfolio to improve long-term prospects 9
From pure-play small molecule company to biopharmaceutical 10
Expansion into CNS and oncology 11
Breaking into the US 12
A 'younger' product portfolio 13
Re-structuring bolsters financial performance 14
SWOT analysis 17
Strengths 17
Growth prospects of Erbitux 17
Broad portfolio supported by pipeline 18
Continued sales growth from off-patent products 18
Weaknesses 18
Over reliance on Erbitux to drive growth 18
Opportunities 19
Expansion of oncology portfolio through continued growth of Erbitux and development of pipeline candidates 19
Continued improvement of operating profit margin 19
Use high revenues to pursue licensing deals to further bolster portfolio 20
Pursue M&A opportunities to build consumer health and life sciences businesses 20
Threats 20
Increasing competition from biosimilars is affecting the growth prospects of Merck KGaA's therapeutic protein franchise 20
• CHAPTER 3 QUARTERLY NEWS UPDATE 25
• Product developments 25
Deals and alliances 26
Product deals 26
Technology deals 31
M&A activity 33
Company announcements 34
Future product milestones 38
• CHAPTER 4 COMPANY INTRODUCTION 39
• Key findings 39
Background 40
Key corporate developments 40
M&A history 41
Merck-Serono Biopharmaceuticals 41
Divestment of generics business 41
Streamlined focus 42
Current corporate structure 42
Pharmaceuticals 43
Branded prescription pharmaceuticals 43
Consumer health 43
Chemicals 44
Performance & life science chemicals 44
Liquid crystals 44
Pharmaceuticals business unit structure 45
• CHAPTER 5 COMPANY SALES 46
• Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2001-13 48
Product analysis 50
Product analysis, 2001-07 50
Product analysis, 2007-13 53
Therapy area analysis 56
Therapy area analysis, 2001-07 57
Therapy area analysis, 2007-13 59
Therapy area focus, 2001-13 61
Geographic analysis 63
Geographic analysis, 2001-07 64
Geographic analysis, 2007-13 66
Geographic focus, 2001-13 68
Launch/core/expiry analysis 69
Explanation of launch/core/expiry analysis 69
Launch analysis, 2007-13 70
Core analysis, 2007-13 71
Expiry analysis, 2007-13 72
Launch/core/expiry configuration, 2007-13 73
Molecule type analysis 75
Molecule type analysis, 2001-07 76
Molecule type analysis, 2007-13 77
Externalization analysis 79
Externalization analysis, 2001-07 80
Externalization analysis, 2007-13 81
• CHAPTER 6 COMPANY FINANCIALS 83
• Key findings 83
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 84
Financial statements, 2001-07 86
Profit and loss account, 2001-07 86
Balance sheet, 2001-07 88
Operating costs and profit analysis 90
Operating costs and profit analysis, 2001-07 91
Operating cost ratio and profit margin analysis, 2001-07 92
Operating cost ratio and profit margin analysis, 2007-13 93
Operating costs and profit analysis, 2007-13 95
Return on capital employed analysis 97
Capital employed analysis, 2001-07 98
Return on capital employed (RoCE) analysis, 2001-07 100
Market capitalization analysis 103
Market capitalization analysis, 2001-07 103
Total shareholder returns analysis, 2001-07 104
• CHAPTER 7 KEY PRODUCTS AND COMPETITORS 106
• Key findings 106
Overview 107
CNS 108
Rebif 108
Overview 108
Sales forecast 109
Mylinax 113
Overview 113
Sales forecast 114
safinamide 117
Overview 117
Sales forecast 118
Oncology 121
Erbitux 121
Overview 121
Sales forecast 122
Cardiovascular 124
Concor & Concor-Plus 124
Overview 124
Sales forecast 125
Kuvan 126
Overview 126
Sales forecast 127
Urology & gender-specific health 128
Gonal-F 128
Overview 128
Sales forecast 129
Endocrine, metabolic and genetic disorders 132
Glucophage & Glucovance 132
Overview 132
Sales forecast 133
• CHAPTER 8 APPENDIX 134
• R&D pipeline 134
References 135
Papers 135
Company releases 135
Datamonitor reports 135
News articles 136
Abbreviations 136
Exchange rates 137
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaVitae Market
http://www.reportsandreports.com/reports/8512-merck-kgaa-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Merck & Co. Inc: PharmaVitae Profile
http://www.reportsandreports.com/reports/8184-merck-co-inc-pharmavitae-profile.html
Merck KGaA-Detailed Product Pipeline
http://www.reportsandreports.com/reports/30214-merck-kgaa-detailed-product-pipeline.html
Merck KGaA-Company Report
http://www.reportsandreports.com/reports/5761-merck-kgaa-company-report.html
Merck KGaA-Deals & Alliances Report
http://www.reportsandreports.com/reports/32118-merck-kgaa-deals-alliances-report.html
Merck KGaA - SWOT Analysis
http://www.reportsandreports.com/reports/1960-merck-kgaa-swot-analysis.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Merck KGaA: PharmaVitae Profile now available at ReportsandReports here
News-ID: 147621 • Views: …
More Releases from ReportsandReports
The Growing Importance of Smart Wearable Equipment - Global Market: Today's Worl …
The report presents detailed information regarding the prominent players and potential competitors in the Smart Wearable Equipment - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses…
Vegetable Glycerin - Global Market 2023 Driving Factors Forecast Research 2029
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Vegetable Glycerin - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role…
Underground Concrete - Global Market Booming Worldwide with Latest Trend and Fut …
The report presents detailed information regarding the prominent players and potential competitors in the Underground Concrete - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue,…
Eucalyptol - Global Market was Led by the Solution Category
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Eucalyptol - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role in…
More Releases for Merck
Swine Fever Vaccine Market Detailed in New Research Report By 2032 | Merck & Co. …
🚀 𝐒𝐰𝐢𝐧𝐞 𝐅𝐞𝐯𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟗% (𝟐𝟎𝟐𝟓 - 𝟐𝟎𝟑𝟐)
The Swine Fever Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
» 70% efforts of Primary Research
» 15% efforts of Secondary Research
» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies
📈…
Women's Health Market Industry Growth Report to 2031 Merck KGaA, Merck & Co, Fer …
[New York, December 2024] Women's Health encompasses a broad spectrum of medical and wellness services tailored to address the unique health needs of women across all life stages. This crucial sub-market of healthcare highlights the necessity for specialized treatments, preventive care, and holistic wellness approaches that resonate with today's female patients. Women's Health isn't just a niche sector; it represents a burgeoning field within healthcare, mirrored by an increasing global…
Laboratory Syringe Market Size, Growing Demand to 2036 GESERCO, Merck Millipore, …
A laboratory syringe is a precise instrument commonly used for the accurate measurement and transfer of liquids or gases in scientific experiments. Unlike standard medical syringes, laboratory syringes are often made of materials such as glass or high-quality plastic to withstand chemical reactions and offer greater clarity for observing contents. They come in a range of sizes, from as small as 1 mL to over 100 mL, and are often…
Leuprorelin Acetate Market Analysis By Top Keyplayers - Merck, Takeda, MediGene, …
The "Leuprorelin Acetate Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Leuprorelin Acetate Market, 2024-2031
Verified Market Research's most recent report, "Leuprorelin Acetate Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth…
Avelumab Market Analysis By Top Key Players - Merck, Pfizer, Merck
The "Avelumab Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Avelumab Market, 2024-2031
Verified Market Research's most recent report, "Avelumab Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the…
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI.
The Nanobodies market report analyse the manufacturing cost of the…
